ZA200100622B - Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine and or phenylacetate - Google Patents
Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine and or phenylacetate Download PDFInfo
- Publication number
- ZA200100622B ZA200100622B ZA2001/00622A ZA200100622A ZA200100622B ZA 200100622 B ZA200100622 B ZA 200100622B ZA 2001/00622 A ZA2001/00622 A ZA 2001/00622A ZA 200100622 A ZA200100622 A ZA 200100622A ZA 200100622 B ZA200100622 B ZA 200100622B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- pharmaceutical composition
- day
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/121,567 US6258849B1 (en) | 1998-07-23 | 1998-07-23 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| PCT/US1999/015017 WO2000004894A2 (en) | 1998-07-23 | 1999-07-02 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200100622B true ZA200100622B (en) | 2002-06-26 |
Family
ID=22397538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2001/00622A ZA200100622B (en) | 1998-07-23 | 2001-01-22 | Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine and or phenylacetate |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6258849B1 (enExample) |
| EP (1) | EP1098643B1 (enExample) |
| JP (2) | JP2002521329A (enExample) |
| KR (4) | KR100417100B1 (enExample) |
| CN (3) | CN1191064C (enExample) |
| AT (1) | ATE257378T1 (enExample) |
| AU (1) | AU759278B2 (enExample) |
| BR (1) | BR9912356A (enExample) |
| CA (1) | CA2336945C (enExample) |
| DE (1) | DE69914084T2 (enExample) |
| DK (1) | DK1098643T3 (enExample) |
| EA (1) | EA004179B1 (enExample) |
| ES (1) | ES2214866T3 (enExample) |
| ID (1) | ID28160A (enExample) |
| IL (1) | IL140848A (enExample) |
| NZ (1) | NZ509244A (enExample) |
| PL (1) | PL213698B1 (enExample) |
| PT (1) | PT1098643E (enExample) |
| WO (1) | WO2000004894A2 (enExample) |
| ZA (1) | ZA200100622B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127419A (en) * | 1998-11-23 | 2000-10-03 | Burzynski; Stanislaw R. | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis |
| DE60115465T2 (de) | 2000-08-29 | 2006-08-03 | Nobex Corp. | Immunoregulierende verbindungen, deren derivate und ihre verwendung |
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| US20060246016A1 (en) * | 2003-05-28 | 2006-11-02 | Burzynski Stanislaw R | Toothpaste containing anticancer agents |
| US7087219B2 (en) * | 2003-05-28 | 2006-08-08 | Stanislaw R. Burzynski | Toothpaste containing anticancer agents |
| US7772108B2 (en) * | 2004-06-25 | 2010-08-10 | Samsung Electronics Co., Ltd. | Interconnection structures for semiconductor devices and methods of forming the same |
| EP1773767B1 (en) | 2004-07-07 | 2016-03-09 | Biocon Limited | Synthesis of azo bonded immunoregulatory compounds |
| JP2008508300A (ja) * | 2004-07-28 | 2008-03-21 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗癌剤としての３−ブロモ−２−オキソプロピオン酸プロピルおよび誘導体 |
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
| DK3263100T3 (da) | 2009-04-03 | 2020-05-11 | Ocera Therapeutics Inc | L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf |
| AU2010258888B2 (en) | 2009-06-08 | 2014-08-07 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| MX360062B (es) | 2010-10-06 | 2018-10-22 | Ocera Therapeutics Inc | Metodos de elaboracion de fenilacetato de l-ornitina. |
| CN107206021B (zh) | 2014-11-24 | 2021-09-03 | Ucl商业有限公司 | 使用降氨疗法治疗与肝星状细胞激活相关的疾病 |
| EP3337473A4 (en) | 2015-08-18 | 2019-04-17 | Ocera Therapeutics, Inc. | TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE |
| EP3397960B1 (en) * | 2015-12-30 | 2020-01-29 | Société des Produits Nestlé S.A. | Method for determining fat free body mass |
| US10624869B2 (en) | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
| CN110740988A (zh) | 2017-05-11 | 2020-01-31 | 欧塞拉治疗有限公司 | 制备l-鸟氨酸苯乙酸盐的方法 |
| US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
| KR20230124107A (ko) * | 2017-06-12 | 2023-08-24 | 스탠니슬로우 알 벌진스키 | 연수막 질환의 치료 방법 |
| US20230190694A1 (en) * | 2021-11-03 | 2023-06-22 | Stanislaw R. Burzynski | Compositions for and methods of precision cancer treatment |
| CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
| CN116491472B (zh) * | 2022-12-14 | 2024-07-26 | 上海交通大学医学院附属第九人民医院 | 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途 |
| WO2024263966A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating pancreatic cancer |
| WO2024263963A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating head and neck cancer |
| WO2024263960A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4470970A (en) | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
| US5244922A (en) | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
| US5254587A (en) | 1990-09-04 | 1993-10-19 | Burzynski Stanislaw R | Methods for treating AIDS |
| US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| ATE310505T1 (de) | 1996-05-14 | 2005-12-15 | Stanislaw R Burzynski | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
-
1998
- 1998-07-23 US US09/121,567 patent/US6258849B1/en not_active Expired - Fee Related
-
1999
- 1999-07-02 KR KR10-2003-7002799A patent/KR100417100B1/ko not_active Expired - Fee Related
- 1999-07-02 AT AT99932179T patent/ATE257378T1/de active
- 1999-07-02 KR KR10-2003-7002798A patent/KR100414587B1/ko not_active Expired - Fee Related
- 1999-07-02 CN CNB99811314XA patent/CN1191064C/zh not_active Expired - Fee Related
- 1999-07-02 IL IL14084899A patent/IL140848A/xx not_active IP Right Cessation
- 1999-07-02 DE DE69914084T patent/DE69914084T2/de not_active Expired - Lifetime
- 1999-07-02 CA CA002336945A patent/CA2336945C/en not_active Expired - Fee Related
- 1999-07-02 DK DK99932179T patent/DK1098643T3/da active
- 1999-07-02 EA EA200100168A patent/EA004179B1/ru not_active IP Right Cessation
- 1999-07-02 WO PCT/US1999/015017 patent/WO2000004894A2/en not_active Ceased
- 1999-07-02 CN CNB2004100616005A patent/CN100400039C/zh not_active Expired - Fee Related
- 1999-07-02 AU AU48542/99A patent/AU759278B2/en not_active Ceased
- 1999-07-02 PL PL345959A patent/PL213698B1/pl unknown
- 1999-07-02 PT PT99932179T patent/PT1098643E/pt unknown
- 1999-07-02 KR KR10-2003-7002800A patent/KR100417101B1/ko not_active Expired - Fee Related
- 1999-07-02 BR BR9912356-8A patent/BR9912356A/pt not_active Application Discontinuation
- 1999-07-02 ID IDW20010174A patent/ID28160A/id unknown
- 1999-07-02 KR KR10-2001-7001021A patent/KR100399658B1/ko not_active Expired - Fee Related
- 1999-07-02 NZ NZ509244A patent/NZ509244A/xx not_active IP Right Cessation
- 1999-07-02 EP EP99932179A patent/EP1098643B1/en not_active Expired - Lifetime
- 1999-07-02 CN CNA2004100032827A patent/CN1605334A/zh active Pending
- 1999-07-02 ES ES99932179T patent/ES2214866T3/es not_active Expired - Lifetime
- 1999-07-02 JP JP2000560887A patent/JP2002521329A/ja active Pending
-
2001
- 2001-01-22 ZA ZA2001/00622A patent/ZA200100622B/en unknown
- 2001-05-22 US US09/863,035 patent/US6943192B2/en not_active Expired - Lifetime
-
2010
- 2010-10-08 JP JP2010228241A patent/JP2011051993A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6258849B1 (en) | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | |
| EP1243262B1 (en) | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain | |
| KR20120027371A (ko) | Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물 | |
| US8912167B2 (en) | Heparin-based compositions and methods for the inhibition of metastasis | |
| HK1037142B (en) | Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases | |
| Cedarbaum et al. | Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys | |
| US4918193A (en) | Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion | |
| MXPA99000255A (en) | Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate | |
| US7226766B2 (en) | S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide | |
| IL141645A (en) | Pharmaceutical preparations containing 3'-desamino-3 '- (2-methoxymorpolino) doxorubicin for the treatment of liver tumors | |
| EP1649855A1 (en) | Medicinal composition | |
| WO2025073968A1 (en) | Combination of roginolisib with a malt1-gls inhibitor | |
| JPS61129124A (ja) | 抗腫瘍剤 | |
| HK1074771A (en) | Use of composition in the manufacture of a medicament for treating neoplastic disease | |
| TO et al. | Metabolic Aspects and Medical Treatment for Urinary Tract Stones | |
| LL0S0 et al. | PRECLINICAL STUDIES ON ANTINEOPLASTON AS2-1 AND |